Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
Do-Youn Oh, Se-Hoon Lee, Sae-Won Han, Mi-Jung Kim, Tae-Min Kim, Tae-You Kim, Dae Seog Heo, Miyuki Yuasa, Yasuo Yanagihara, Yung-Jue Bang
Cancer Res Treat. 2015;47(4):607-615.   Published online 2015 Feb 26     DOI: https://doi.org/10.4143/crt.2014.249
Citations to this article as recorded by Crossref logo
An update on investigational therapies that target STAT3 for the treatment of cancer
Matteo Santoni, Francesca Miccini, Alessia Cimadamore, Francesco Piva, Francesco Massari, Liang Cheng, Antonio Lopez-Beltran, Rodolfo Montironi, Nicola Battelli
Expert Opinion on Investigational Drugs.2021; 30(3): 245.     CrossRef
Radiation induces an inflammatory response that results in STAT3-dependent changes in cellular plasticity and radioresistance of breast cancer stem-like cells
Kimberly M. Arnold, Lynn M. Opdenaker, Nicole J. Flynn, Daniel Kwesi Appeah, Jennifer Sims-Mourtada
International Journal of Radiation Biology.2020; 96(4): 434.     CrossRef
Quinazoline Ligands Induce Cancer Cell Death through Selective STAT3 Inhibition and G-Quadruplex Stabilization
Jan Jamroskovic, Mara Doimo, Karam Chand, Ikenna Obi, Rajendra Kumar, Kristoffer Brännström, Mattias Hedenström, Rabindra Nath Das, Almaz Akhunzianov, Marco Deiana, Kazutoshi Kasho, Sebastian Sulis Sato, Parham L. Pourbozorgi, James E. Mason, Paolo Medini
Journal of the American Chemical Society.2020; 142(6): 2876.     CrossRef
Phosphotyrosine isosteres: past, present and future
Robert A. Cerulli, Joshua A. Kritzer
Organic & Biomolecular Chemistry.2020; 18(4): 583.     CrossRef
Anticancer activity of dietary xanthone α-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1
Hai Zhang, Yu-ping Tan, Lin Zhao, Lun Wang, Nai-jie Fu, Song-ping Zheng, Xiao-fei Shen
Cell Death & Disease.2020;[Epub]     CrossRef
JAK/STAT signaling in hepatocellular carcinoma
Justin Jit Hin Tang, Dexter Kai Hao Thng, Jhin Jieh Lim, Tan Boon Toh
Hepatic Oncology.2020; 7(1): HEP18.     CrossRef
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
Azucena Salas, Cristian Hernandez-Rocha, Marjolijn Duijvestein, William Faubion, Dermot McGovern, Severine Vermeire, Stefania Vetrano, Niels Vande Casteele
Nature Reviews Gastroenterology & Hepatology.2020; 17(6): 323.     CrossRef
Targeting STAT3 in cancer and autoimmune diseases
Tohid Gharibi, Zohreh Babaloo, Arezoo Hosseini, Meghdad Abdollahpour-alitappeh, Vida Hashemi, Faroogh Marofi, Kazem Nejati, Behzad Baradaran
European Journal of Pharmacology.2020; 878: 173107.     CrossRef
Betacellulin drives therapy resistance in glioblastoma
Qiwen Fan, Zhenyi An, Robyn A Wong, Xujun Luo, Edbert D Lu, Albert Baldwin, Manasi K Mayekar, Franziska Haderk, Kevan M Shokat, Trever G Bivona, William A Weiss
Neuro-Oncology.2020; 22(4): 457.     CrossRef
A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction
Soo Kyung Park, Woong Sub Byun, Seungbeom Lee, Young Taek Han, Yoo-Seong Jeong, Kyungkuk Jang, Suk-Jae Chung, Jeeyeon Lee, Young-Ger Suh, Sang Kook Lee
Biochemical Pharmacology.2020; 178: 114053.     CrossRef
STAT3 Pathway in Gastric Cancer: Signaling, Therapeutic Targeting and Future Prospects
Milad Ashrafizadeh, Ali Zarrabi, Sima Orouei, Vahideh Zarrin, Ebrahim Rahmani Moghadam, Amirhossein Zabolian, Shima Mohammadi, Kiavash Hushmandi, Yashar Gharehaghajlou, Pooyan Makvandi, Masoud Najafi, Reza Mohammadinejad
Biology.2020; 9(6): 126.     CrossRef
Towards the Inhibition of Protein–Protein Interactions (PPIs) in STAT3: Insights into a New Class of Benzothiadiazole Derivatives
Matteo Mori, Ettore Gilardoni, Luca Regazzoni, Alessandro Pedretti, Diego Colombo, Gary Parkinson, Akira Asai, Fiorella Meneghetti, Stefania Villa, Arianna Gelain
Molecules.2020; 25(15): 3509.     CrossRef
STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy
Ping-Lian Yang, Lu-Xin Liu, En-Min Li, Li-Yan Xu
Cancers.2020; 12(9): 2459.     CrossRef

Progress in Understanding the IL-6/STAT3 Pathway in Colorectal Cancer

Yan Lin, Ziqin He, Jiazhou Ye, Ziyu Liu, Xiaomin She, Xing Gao, Rong Liang
OncoTargets and Therapy.2020; Volume 13: 13023.     CrossRef
Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes
Chen-Hao Zhang, Ming Li, You-Pei Lin, Qiang Gao
Current Gene Therapy.2020; 20(2): 84.     CrossRef
Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma
Yung-Hsing Huang, Mohammad Vakili, Ommoleila Molavi, Yuen Morrissey, Chengsheng Wu, Igor Paiva, Amir Soleimani, Forugh Sanaee, Afsaneh Lavasanifar, Raymond Lai
Cancers.2019; 11(2): 248.     CrossRef
Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma
Changhoon Yoo, Jihoon Kang, Ho Yeong Lim, Jee Hyun Kim, Myung-Ah Lee, Kyung-Hun Lee, Tae-You Kim, Baek-Yeol Ryoo
Cancer Research and Treatment.2019; 51(2): 510.     CrossRef
IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2
Xiaodong Chen, Feng Chen, Yu Ren, Guobin Weng, Lijun Xu, Xiang Xue, Peter C. Keng, Soo Ok Lee, Yuhchyau Chen
Journal of Cancer Research and Clinical Oncology.2019; 145(6): 1471.     CrossRef
Proton pump inhibitor: The dual role in gastric cancer
Moon Kyung Joo, Jong-Jae Park, Hoon Jai Chun
World Journal of Gastroenterology.2019; 25(17): 2058.     CrossRef
Transcriptional Reprogramming and Novel Therapeutic Approaches for Targeting Prostate Cancer Stem Cells
Gianluca Civenni, Domenico Albino, Dheeraj Shinde, Ramiro Vázquez, Jessica Merulla, Aleksandra Kokanovic, Sarah N. Mapelli, Giuseppina M. Carbone, Carlo V. Catapano
Frontiers in Oncology.2019;[Epub]     CrossRef
STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
Jiang-Jiang Qin, Li Yan, Jia Zhang, Wei-Dong Zhang
Journal of Experimental & Clinical Cancer Research.2019;[Epub]     CrossRef
JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors
Emily A. Irey, Chelsea M. Lassiter, Nicholas J. Brady, Pavlina Chuntova, Ying Wang, Todd P. Knutson, Christine Henzler, Thomas S. Chaffee, Rachel I. Vogel, Andrew C. Nelson, Michael A. Farrar, Kathryn L. Schwertfeger
Proceedings of the National Academy of Sciences.2019; 116(25): 12442.     CrossRef
Elevated HOX gene expression in acute myeloid leukemia is associated with NPM1 mutations and poor survival
Ádám Nagy, Ágnes Ősz, Jan Budczies, Szilvia Krizsán, Gergely Szombath, Judit Demeter, Csaba Bödör, Balázs Győrffy
Journal of Advanced Research.2019; 20: 105.     CrossRef
Antitumor activity of novel pyrazole-based small molecular inhibitors of the STAT3 pathway in patient derived high grade glioma cells
Liang Zhang, Timothy E. Peterson, Victor M. Lu, Ian F. Parney, David J. Daniels, Ilya Ulasov
PLOS ONE.2019; 14(7): e0220569.     CrossRef
Inhibition of Stat3 Signaling Pathway by Natural Product Pectolinarigenin Attenuates Breast Cancer Metastasis
Yali Li, Cailing Gan, Yange Zhang, Yan Yu, Chen Fan, Yuanle Deng, Qianyu Zhang, Xi Yu, Yiwen Zhang, Liqun Wang, Fang He, Yongmei Xie, Tinghong Ye, Wenya Yin
Frontiers in Pharmacology.2019;[Epub]     CrossRef
Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status
Tadashi Ashizawa, Akira Iizuka, Chie Maeda, Emiko Tanaka, Ryota Kondou, Haruo Miyata, Takashi Sugino, Takuya Kawata, Shoichi Deguchi, Koichi Mitsuya, Nakamasa Hayashi, Akira Asai, Mamoru Ito, Ken Yamaguchi, Yasuto Akiyama
Immunology Letters.2019; 216: 43.     CrossRef
Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents
Arianna Gelain , Matteo Mori , Fiorella Meneghetti , Stefania Villa
Current Medicinal Chemistry.2019; 26(27): 5165.     CrossRef
The effects of signal transducer and activator of transcription three mutations on human platelets
Floor E. Aleva, Frank L. van de Veerdonk, Yang Li, Rahajeng N. Tunjungputri, Sami Simons, Philip G. De Groot, Mihai M. Netea, Yvonne F. Heijdra, Quirijn de Mast, André J.A.M. van der Ven
Platelets.2018; 29(6): 602.     CrossRef
Mechanisms Linking Obesity and Thyroid Cancer Development and Progression in Mouse Models
Won Gu Kim, Sheue-yann Cheng
Hormones and Cancer.2018; 9(2): 108.     CrossRef
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Daniel E. Johnson, Rachel A. O'Keefe, Jennifer R. Grandis
Nature Reviews Clinical Oncology.2018; 15(4): 234.     CrossRef
Arsenic trioxide attenuates STAT-3 activity and epithelial-mesenchymal transition through induction of SHP-1 in gastric cancer cells
Sung Ho Kim, Hyo Soon Yoo, Moon Kyung Joo, Taehyun Kim, Jong-Jae Park, Beom Jae Lee, Hoon Jai Chun, Sang Woo Lee, Young-Tae Bak
BMC Cancer.2018;[Epub]     CrossRef
Linker Variation and Structure–Activity Relationship Analyses of Carboxylic Acid-based Small Molecule STAT3 Inhibitors
Francisco Lopez-Tapia, Christine Brotherton-Pleiss, Peibin Yue, Heide Murakami, Ana Carolina Costa Araujo, Bruna Reis dos Santos, Erin Ichinotsubo, Anna Rabkin, Raj Shah, Megan Lantz, Suzie Chen, Marcus A. Tius, James Turkson
ACS Medicinal Chemistry Letters.2018; 9(3): 250.     CrossRef
Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma Immunotherapy
Mario M. Soldevilla, Fernando Pastor
Molecular Therapy.2018; 26(3): 675.     CrossRef
Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?
Jenny D. Beebe, Jing-Yuan Liu, Jian-Ting Zhang
Pharmacology & Therapeutics.2018; 191: 74.     CrossRef
Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs
Massimo Gadina, Catrina Johnson, Daniella Schwartz, Michael Bonelli, Sarfaraz Hasni, Yuka Kanno, Paul Changelian, Arian Laurence, John J. O'Shea
Journal of Leukocyte Biology.2018; 104(3): 499.     CrossRef
Targeting JAK-STAT signal transduction in IBD
Christoffer Soendergaard, Fredrik Holmberg Bergenheim, Jakob Tveiten Bjerrum, Ole Haagen Nielsen
Pharmacology & Therapeutics.2018; 192: 100.     CrossRef
“Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
Emira Bousoik, Hamidreza Montazeri Aliabadi
Frontiers in Oncology.2018;[Epub]     CrossRef
Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance
Megha Budhwani, Roberta Mazzieri, Riccardo Dolcetti
Frontiers in Oncology.2018;[Epub]     CrossRef
STAT3 in Breast Cancer Onset and Progression: A Matter of Time and Context
Ilenia Segatto, Gustavo Baldassarre, Barbara Belletti
International Journal of Molecular Sciences.2018; 19(9): 2818.     CrossRef
Suppression of STAT3 signaling promotes cellular reprogramming into insulin-producing cells induced by defined transcription factors
Masaki Miura, Takeshi Miyatsuka, Takehiro Katahira, Shugo Sasaki, Luka Suzuki, Miwa Himuro, Yuya Nishida, Yoshio Fujitani, Taka-aki Matsuoka, Hirotaka Watada
EBioMedicine.2018; 36: 358.     CrossRef
Aptamer-iRNAs as Therapeutics for Cancer Treatment
Mario Soldevilla, Daniel Meraviglia-Crivelli de Caso, Ashwathi Menon, Fernando Pastor
Pharmaceuticals.2018; 11(4): 108.     CrossRef
A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
Anthony Tolcher, Keith Flaherty, Geoffrey I. Shapiro, Jordan Berlin, Thomas Witzig, Thomas Habermann, Andrea Bullock, Edwin Rock, Agnes Elekes, Chester Lin, Dusan Kostic, Naoto Ohi, Drew Rasco, Kyriakos P. Papadopoulos, Amita Patnaik, Lon Smith, Gregory M
The Oncologist.2018; 23(6): 658.     CrossRef
Impact of STAT3 phosphorylation in glioblastoma stem cells radiosensitization and patient outcome
Konstantin Masliantsev, Baptiste Pinel, Anaïs Balbous, Pierre-Olivier Guichet, Gaëlle Tachon, Serge Milin, Julie Godet, Mathilde Duchesne, Antoine Berger, Christos Petropoulos, Michel Wager, Lucie Karayan-Tapon
Oncotarget.2018; 9(3): 3968.     CrossRef
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking
Wenying Yu, Chenglong Li, Wenda Zhang, Yuanzheng Xia, Shanshan Li, Jia-yuh Lin, Keqin Yu, Mu Liu, Lei Yang, Jianguang Luo, Yijun Chen, Hongbin Sun, Lingyi Kong
Journal of Medicinal Chemistry.2017; 60(7): 2718.     CrossRef
Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic
Fenil Shah, Derek Logsdon, Richard A. Messmann, Jill C. Fehrenbacher, Melissa L. Fishel, Mark R. Kelley
npj Precision Oncology.2017;[Epub]     CrossRef
Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells
Davide Genini, Lara Brambilla, Erik Laurini, Jessica Merulla, Gianluca Civenni, Shusil Pandit, Rocco D'Antuono, Laurent Perez, David E. Levy, Sabrina Pricl, Giuseppina M. Carbone, Carlo V. Catapano
Proceedings of the National Academy of Sciences.2017; 114(25): E4924.     CrossRef
Identification of novel small molecules that inhibit STAT3-dependent transcription and function
Iryna Kolosenko, Yasmin Yu, Sander Busker, Matheus Dyczynski, Jianping Liu, Martin Haraldsson, Caroline Palm Apergi, Thomas Helleday, Katja Pokrovskaja Tamm, Brent D. G. Page, Dan Grander, Aamir Ahmad
PLOS ONE.2017; 12(6): e0178844.     CrossRef
Antineoplastic effects of CPPTL via the ROS/JNK pathway in acute myeloid leukemia
Hui-Er Gao, Yue Sun, Ya-Hui Ding, Jing Long, Xiao-Lei Liu, Ming Yang, Qing Ji, Ying-Hui Li, Yue Chen, Quan Zhang, Ying-Dai Gao
Oncotarget.2017; 8(24): 38990.     CrossRef
Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation
Verena Leidgens, Judith Proske, Lisa Rauer, Sylvia Moeckel, Kathrin Renner, Ulrich Bogdahn, Markus J. Riemenschneider, Martin Proescholdt, Arabel Vollmann-Zwerenz, Peter Hau, Corinna Seliger
Oncotarget.2017; 8(5): 8250.     CrossRef
Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug
Yu Dong, Takuya Furuta, Hemragul Sabit, Tomohiro Kitabayashi, Shabierjiang Jiapaer, Masahiko Kobayashi, Yasushi Ino, Tomoki Todo, Lei Teng, Atsushi Hirao, Shi-Guang Zhao, Mitsutoshi Nakada
Oncotarget.2017; 8(67): 111728.     CrossRef
Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism
Chengguang Zhao, Huameng Li, Huey-Jen Lin, Shulin Yang, Jiayuh Lin, Guang Liang
Trends in Pharmacological Sciences.2016; 37(1): 47.     CrossRef
Targeting transcription factor STAT3 for cancer prevention and therapy
Edna Zhi Pei Chai, Muthu K. Shanmugam, Frank Arfuso, Arunasalam Dharmarajan, Chao Wang, Alan Prem Kumar, Ramar Perumal Samy, Lina H.K. Lim, Lingzhi Wang, Boon Cher Goh, Kwang Seok Ahn, Kam Man Hui, Gautam Sethi
Pharmacology & Therapeutics.2016; 162: 86.     CrossRef
Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma
Chiara Lazzari, Alberto Verlicchi, Anastasios Gkountakos, Sara Pilotto, Mariacarmela Santarpia, Imane Chaib, Jose Luis Ramirez Serrano, Santiago Viteri, Daniela Morales-Espinosa, Claudio Dazzi, Filippo de Marinis, Peng Cao, Niki Karachaliou, Rafael Rosell
Pulmonary Therapy.2016; 2(1): 1.     CrossRef
Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer
Zilma Escobar, Anders Bjartell, Giacomo Canesin, Susan Evans-Axelsson, Olov Sterner, Rebecka Hellsten, Martin H Johansson
Journal of Medicinal Chemistry.2016; 59(10): 4551.     CrossRef
A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer
Andres Rojas, Pingyu Zhang, Ying Wang, Wai Chin Foo, Nina M. Muñoz, Lianchun Xiao, Jing Wang, Gregory J. Gores, Mien-Chie Hung, Boris Blechacz
Neoplasia.2016; 18(6): 371.     CrossRef
Novel STAT 3 inhibitors for treating gastric cancer
Catherine Cafferkey, Ian Chau
Expert Opinion on Investigational Drugs.2016; 25(9): 1023.     CrossRef
‘Acute myeloid leukemia: a comprehensive review and 2016 update’
I De Kouchkovsky, M Abdul-Hay
Blood Cancer Journal.2016; 6(7): e441.     CrossRef
Recent updates of precision therapy for gastric cancer: Towards optimal tailored management
Moon Kyung Joo, Jong-Jae Park, Hoon Jai Chun
World Journal of Gastroenterology.2016; 22(19): 4638.     CrossRef
Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease
Malgorzata Szelag, Anna Piaszyk-Borychowska, Martyna Plens-Galaska, Joanna Wesoly, Hans A.R. Bluyssen
Oncotarget.2016; 7(30): 48788.     CrossRef
Cell-cell and cell-matrix adhesion in survival and metastasis: Stat3 versus Akt
Maximilian Niit, Victoria Hoskin, Esther Carefoot, Mulu Geletu, Rozanne Arulanandam, Bruce Elliott, Leda Raptis
Biomolecular Concepts.2015; 6(5-6): 383.     CrossRef
Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma
Takuji Okusaka, Hideki Ueno, Masafumi Ikeda, Shuichi Mitsunaga, Masato Ozaka, Hiroshi Ishii, Osamu Yokosuka, Yoshihiko Ooka, Ryo Yoshimoto, Yasuo Yanagihara, Kiwamu Okita
Hepatology Research.2015; 45(13): 1283.     CrossRef
STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells
Heng Yang, Takahiro Yamazaki, Federico Pietrocola, Heng Zhou, Laurence Zitvogel, Yuting Ma, Guido Kroemer
Cancer Research.2015; 75(18): 3812.     CrossRef